论文部分内容阅读
[目的]探讨爱迪联合放射综合治疗老年中晚期食管癌的疗效和安全性。[方法]80例老年中晚期食管癌患者按随机数字表法分为观察组和对照组各40例。对照组采用单纯放疗,观察组加用爱迪注射液。[结果]观察组近期疗效有效率为77.5%(31/40),对照组为55.0%(11/40),差异有统计学意义(χ2=4.53,P﹤0.05);观察组生活质量有效率为87.5%(35/40),对照组为65.0%(26/40),差异有统计学意义(χ2=5.59,P﹤0.05);观察组毒副反应较轻,Ⅲ～Ⅳ度白细胞减少和食管黏膜反应明显少于对照组,差异有统计学意义(χ2=4.50,P﹤0.05);观察组1年生存率为72.5%(29/40),对照组为47.5%(19/40),差异有统计学意义(χ2=5.21,P﹤0.05)。[结论]爱迪联合放射综合治疗老年中晚期食管癌能明显提高疗效,减轻毒副反应,改善生活质量,延长生存期,更易为老年患者所接受,值得临床推广应用。
[Objective] To investigate the efficacy and safety of Aidi combined with radiotherapy for advanced esophageal cancer in the elderly. [Method] Eighty elderly patients with advanced esophageal cancer were divided into observation group and control group according to random number table method. Control group with radiotherapy alone, the observation group plus Aidi injection. [Results] The effective rate of the curative effect in the observation group was 77.5% (31/40) in the observation group and 55.0% (11/40) in the control group, with significant difference (χ2 = 4.53, P <0.05) In the control group was 65.0% (26/40), the difference was statistically significant (χ2 = 5.59, P <0.05); the observation group had less toxic side effects, Ⅲ ~ Ⅳ leukopenia and The 1-year survival rate was 72.5% (29/40) in the observation group and 47.5% (19/40) in the control group, and the difference was statistically significant (χ2 = 4.50, P0.05) The difference was statistically significant (χ2 = 5.21, P <0.05). [Conclusion] The combination of Aidi and radiotherapy for advanced esophageal cancer in elderly can significantly improve the curative effect, reduce the side effects, improve the quality of life and prolong the survival period, which is more easily accepted by elderly patients and worthy of clinical application.